(NASDAQ: SGMT) Sagimet Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.78%.
Sagimet Biosciences's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast SGMT's revenue for 2027 to be $125,533,372, with the lowest SGMT revenue forecast at $125,533,372, and the highest SGMT revenue forecast at $125,533,372. On average, 2 Wall Street analysts forecast SGMT's revenue for 2028 to be $1,671,284,973, with the lowest SGMT revenue forecast at $555,468,911, and the highest SGMT revenue forecast at $2,787,101,034.
In 2029, SGMT is forecast to generate $7,688,106,004 in revenue, with the lowest revenue forecast at $4,185,529,791 and the highest revenue forecast at $11,190,682,216.